References
- WHO. Vaccines Against Influenza WHO Position Paper. 2012 Nov
- Feng L, Shay DK, Jiang Y, Zhou H, Chen X, Zheng Y, Jiang L, Zhang Q, Lin H, Wang S, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003–2008. Bulletin World Health Organization 2012; 90:279–88B; PMID:22511824; http://dx.doi.org/10.2471/BLT.11.096958
- Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, et al. New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathogens 2013; 9:e1003657; PMID:24130481; http://dx.doi.org/10.1371/journal.ppat.1003657
- Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149–56; PMID:20003926; http://dx.doi.org/10.1016/j.vaccine.2009.11.068
- Matsuzaki Y, Katsushima N, Nagai Y, Shoji M, Itagaki T, Sakamoto M, Kitaoka S, Mizuta K, Nishimura H. Clinical features of influenza C virus infection in children. J Infect Dis 2006; 193:1229–35; PMID:16586359; http://dx.doi.org/10.1086/502973
- WHO. Overview of the Emergence and Characteristics of The Avian Influenza A(H7N9). Virus 2013 May 31
- Bethell D, Saunders D, Jongkaewwattana A, Kramyu J, Thitithayanont A, Wiboon-ut S, Yongvanitchit K, Limsalakpetch A, Kum-Arb U, Uthaimongkol N, et al. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial. PloS One 2013; 8:e59674; PMID:23555741; http://dx.doi.org/10.1371/journal.pone.0059674
- Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013; 11:153; PMID:23800265; http://dx.doi.org/10.1186/1741-7015-11-153
- Guo W, Xu J, Wu J, Zhao S, He H, Shi W, Yu D, Li J, Gao H, Chen J. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus]. Zhonghua Liu Xing Bing Xue Za Zhi=Zhonghua Liuxingbingxue Zazhi 2014; 35:949–52; PMID:25376689
- Liu Y, Wu JY, Wang X, Chen JT, Xia M, Hu W, Zou Y, Yin WD. Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu(R). Human Vaccines Immunotherapeutics 2014; 10:73–82; PMID:24104060; http://dx.doi.org/10.4161/hv.26715
- WHO. Number of confirmed human cases of avian influenza A(H7N9) report to WHO (report 10).25 October 2013
- European Medicines Agency (EMA) Committee for Medicinal Products for Human Use. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96) In: European Committee for Medicinal Products for Human Use, ed., March 12, 1997